Dabur: What to do? - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

Dabur: What to do?

Jun 27, 2003

Dabur India Limited has recently decided to demerge its FMCG and Pharma businesses into two separate companies. The company had also reported its FY03 numbers recently. Let's take a look. On a consolidated basis, Dabur finished FY03 with a 7% topline growth and over 37% net profit growth. The company's operating profit margins improved by a percent, as sales increased at a faster clip compared to expenses. Softer interest rates too reduced the company's debt servicing costs. All this helped the ayurvedic product major post a healthy bottomline growth in FY03.

Consolidated Picture
(Rs m) FY02 FY03 Change
Net Sales 12,810 13,709 7.0%
Other Income 120 72 -40.1%
Expenditure 11,487 12,163 5.9%
Operating Profit (EBDIT) 1,323 1,546 16.9%
Operating Profit Margin (%) 10.3% 11.3%  
Interest 333 261 -21.6%
Depreciation 287 293 2.2%
Profit before Tax 823 1,064 29.2%
Tax (including deffered tax) 136.70 133.30 -2.5%
Profit after Tax 686 930 35.5%
Less: Minority Interest -22 -20  
Net Profit/(Loss) after minority interest 664 911 37.1%
Net profit margin (%) 5.4% 6.8%  
Effective tax rate (%) 16.6% 12.5%  
No. of Shares (eoy) (m) 285.6 285.7  
Diluted earnings per share* 2.4 3.3  
P/E ratio   14.7  

If we look at the performance of its FMCG business (i.e. ayurvedic products, hair oils, oral care, honey, OTC products etc.) and the pharma business (oncology etc.) seperately, we see that almost 85% of Dabur's turnover comes from its FMCG business. This business grew at nearly 5% in FY03, but a grip on operating costs saw operating profits improve by over 21% YoY. This and lower interest outgo helped the FMCG division post over 31% growth at PBT levels. The businesses ROCE doubled to nearly 25% during the year.

On the other hand, the company's pharma business grew at a faster rate (nearly 13%) during FY03, on a lower base. However, realisations were under pressure, as witnessed by the dip in operating margins. Higher staff and advertising costs led to this pressure on margins. The business however, earns higher operating margins than the FMCG division. It finished FY03 with a 10% growth. The ROCE of the pharma business also improved marginally to over 6% from 5% in FY02.

  FMCG business Pharma business
(Rs m) FY02 FY03 Change FY02 FY03 Change
Net Sales 10,003 10,485 4.8% 1,629 1,838 12.8%
Other Income 94 49 -47.6% 45 34 -24.9%
Expenditure 9,140 9,438 3.3% 1,426 1,622 13.7%
Operating Profit (EBDIT) 863 1,047 21.4% 203 216 6.6%
Operating Profit Margin (%) 8.6% 10.0%   12.5% 11.8%  
Interest 167 119 -28.7% 72 52 -28.7%
Depreciation 180 177 -1.4% 30 43 43.7%
Profit before Tax 609 800 31.2% 146 155 6.7%
Tax (including deffered tax) 85 7 -91.6% 26 24 -6.6%
Profit after Tax 525 793 51.1% 120 131 9.6%
Net profit margin (%) 5.2% 7.6%   7.4% 7.1%  
Effective tax rate (%) 13.9% 0.9%   17.7% 15.5%  
No. of Shares (eoy) (m) 285.6 285.7   142.8 142.9  
Diluted earnings per share* 1.8 2.8   0.8 0.9  

The ratio for demerger has been set at 1 share of pharma business for every 2 shares held in the original entity. The shareholders will however, receive FMCG business shares in the ratio of 1:1. The move is aimed at bring in more focus to both businesses, as well as to unlock value for shareholders.

Considering the demerger, even if we give Dabur a valuation of 15 P/E for its FMCG business, the price works out to be around Rs 42 per share and therefore, a market cap to sales of 1.1x. Though this is not a full proof method of arriving at a company's business valuation, it does give some indication of value. This business is the core strength of Dabur currently and going forward it has the capability to grow steadily. However, in the pharma business, the company is at a nascent stage and till date has not shown any remarkable edge in this area. In that light, the value of this business wil not be much. At a conservative 5 P/E, the price of this business will work out to be around Rs 5 per share (taking into consideration the reduction of no. of shares by half).

At the current price of 48, Dabur (consolidated) trades at a P/E of 14.7x FY03 earnings. In our view, the business is already valued by the markets. Further improvement in valuations will come only after more clarity about management strategy post the demerger. Also, the promoters past track record on bringing in professional managers is not too enthusing.

Equitymaster requests your view! Post a comment on "Dabur: What to do?". Click here!


More Views on News

DABUR Announces Quarterly Results (1QFY21); Net Profit Down 6.1% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, DABUR has posted a net profit of Rs 3 bn (down 6.1% YoY). Sales on the other hand came in at Rs 20 bn (down 12.9% YoY). Read on for a complete analysis of DABUR's quarterly results.

DABUR Announces Quarterly Results (4QFY20); Net Profit Down 24.1% (Quarterly Result Update)

May 29, 2020 | Updated on May 29, 2020

For the quarter ended March 2020, DABUR has posted a net profit of Rs 3 bn (down 24.1% YoY). Sales on the other hand came in at Rs 19 bn (down 12.3% YoY). Read on for a complete analysis of DABUR's quarterly results.

DABUR 2018-19 Annual Report Analysis (Annual Result Update)

Sep 30, 2019 | Updated on Sep 30, 2019

Here's an analysis of the annual report of DABUR for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DABUR. Also includes updates on the valuation of DABUR.

More Views on News

Most Popular

Why We Picked This Small-cap Stock for Our Hidden Treasure Subscribers (Profit Hunter)

Sep 17, 2020

This leading household brand will profit big time in a post covid world.

My Top Stock to Buy in this Market Selloff (Profit Hunter)

Sep 22, 2020

The recent correction offers a great opportunity to buy this high conviction smallcap stock.

What Do the Charts Say About Buying Smallcaps Now? (Fast Profits Daily)

Sep 18, 2020

Everyone seems to be excited about buying smallcaps now...but is it the right thing to do? What do the charts tell us? Find out in this video...

How Much Money Do You Need to Be a Professional Trader? (Fast Profits Daily)

Sep 17, 2020

In this video I'll answer a question I get asked often: How much capital do I really need to trade the markets for a living? Let's find out...


Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms


Sep 25, 2020 (Close)